Find out about the latest at Exciva

SERENADA trial to run at up to 60 sites across US, UK, Canada and Europe, targeting 300 patientsExciva brings Series …

28th April 2026

Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round.

Heidelberg, Germany, January 20, 2026 – Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric …

20th January 2026

Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT

12th February 2025

Fiona Hattey joined the Exciva team as Head of Clinical Operations. She has over thirty years of experience in operationalizing clinical trials.

4th November 2024

Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US FDA

1st April 2024

Dr Hans Moebius, co-founder of Exciva, re-joined the team as a Chief Medical Officer bringing with him over thirty years of leadership in Neurology and Psychiatry drug development and translational medicine

1st June 2023

Francisco Orellana, a seasoned professional who has worked in the biotech sector for over twenty years, joined Exciva as Chief Financial Officer

25th October 2022

The US PTO granted a patent to Exciva for its invention of innovative composition of matter with various therapeutic uses in neuropsychiatry

11th October 2022

Exciva successfully completed Phase I study of its proprietary EXV-802 combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist

Uncategorized

26th October 2021

Exciva raises €9 million in Series A round led by Andera Partners

Events

Upcoming and past scientific events.

There are no upcoming events.

Papers

Papers and Publications

13 May, 2025

A Descriptive Statistical Analysis of Neuropsychiatric Symptom Pair Prevalence

Publication by the Exciva team providing detailed quantitative analysis of co-occurrence of neuropsychiatric symptoms.

1 Jun, 2024

Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders

A 2024 review by Jeff Cummings, Krista Lanctôt and colleagues on clinical consensus definition of neuropsychiatric symptoms as well as current and emerging therapies.

26 Feb, 2018

Evaluation of the Safety, Tolerability, and Efficacy of Pimavanserin Versus Placebo in Patients with Alzheimer’s Disease Psychosis

A 2018 proof-of-concept study by Clive Ballard and colleagues on pimavanserin, a drug mechanistically similar to EXV-801

22 Sep, 2015

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia

A seminal 2015 publication by Jeff Cummings, Constantine Lyketsos and colleagues that spurred interest in development of dextromethorphan-based therapies for treatment of neuropsychiatric symptoms in dementia